Envudeucitinib Misses Overall SLE Endpoints; Biomarker Subgroup Separates

Company: Alumis · Drug: Envudeucitinib · Trial: LUMUS (Phase 2b) · Indication: Systemic Lupus Erythematosus · Date: September 1, 2026 Summary Alumis reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet its Week-48 BICLA primary endpoint or…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK – $1B SiranBio Oligo Deal